6-Chloro-naphthalene-2-carbonyl chloride | 87700-59-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 6-Chloro-naphthalene-2-carbonyl chloride
• 英文别名: 6-Chloronaphthalene-2-carbonyl chloride
• CAS: 87700-59-2
• 化学式: C₁₁H₆Cl₂O
• 分子量: 225.074
• InChiKey: HSJYCKQRDMEYKC-UHFFFAOYSA-N

物化性质

• 沸点：
  341.5±15.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-Chloro-naphthalene-2-carbonyl chloride 、 苯胺 以 苯 为溶剂， 生成
  参考文献：
  名称：

  Ananthakrishnanadar, P.; Varghesedharumaraj, G., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. 22, # 5, p. 506 - 507

  摘要：

  DOI：

文献信息

• [EN] ARYLCARBOXAMIDES AND USES THEREOF<br/>[FR] ARYLCARBOXAMIDES ET LEURS UTILISATIONS
  申请人：INCEPTION 1 INC

  公开号：WO2017192304A1

  公开（公告）日：2017-11-09

  The present disclosure is directed to compounds of formula (I): or a pharmaceutically acceptable salt, solvate or solvate of the salt thereof. Compounds of formula (I) are inhibitors of NOX4 and are useful in the treatment of fibrotic diseases such as scleroderma; lung disease, such as pulmonary fibrosis including idiopathic pulmonary fibrosis (IPF); heart disease, such as heart failure due to ischaemic heart disease, valvular heart disease and hypertensive heart disease, diabetic cardiomyopathy and hypertension; liver disease, such as cirrhosis of the liver; and kidney disease, such as progressive kidney disease glomerulonephritis and diabetic nephropathy; and eye disease such as diabetic retinopathy; skin or subcutaneous scarring, such as keloids, adhesions, hypertrophic scarring or cosmetic scarring; or as an adjuvant or anti-fibrotic in pancreatic cancer to increase chemotherapeutic drug penetration by reducing the density of the connective tissue stroma.

  本公开涉及的化合物具有以下结构式（I）：或其药学上可接受的盐、溶剂或该盐的溶剂。结构式（I）的化合物是NOX4的抑制剂，可用于治疗纤维化疾病，如硬皮病；肺部疾病，如肺纤维化，包括特发性肺纤维化（IPF）；心脏疾病，如缺血性心脏病、瓣膜性心脏病和高血压性心脏病、糖尿病性心肌病和高血压；肝脏疾病，如肝硬化；肾脏疾病，如进行性肾脏疾病肾小球肾炎和糖尿病肾病；眼部疾病，如糖尿病视网膜病变；皮肤或皮下疤痕，如瘢痕、粘连、肥厚性瘢痕或美容瘢痕；或作为胰腺癌的辅助治疗或抗纤维化剂，通过减少结缔组织基质密度来增加化疗药物的渗透性。
• Liquid crystal compounds having naphthalene nucleus
  申请人：Showa Shell Sekiyu Kabushiki Kaisha

  公开号：EP0339987A2

  公开（公告）日：1989-11-02

  Novel ferroelectric liquid crystal compounds which may realize a stable molecular orientation which makes it possible to give a definite light-dark contrast in the no electric field state and attain a definite threshold property as well as hysterisis, and for making it possible to attain the dynamic drivinng as well as the high speed of response, owing to tri-stable phase thereof, of the general formulae (I) and (II) in which R₁ means an alkyl, alkoxy or alkyloxycarbonyl each of 1-20 carbon atoms, R₂ means optically active

  通式(I)和(II)的新型铁电液晶化合物，其可实现稳定的分子取向，从而有可能在无电场状态下产生明确的明暗对比，并获得明确的阈值特性以及滞后性，并且由于其三相稳定，有可能获得动态驱动以及高速响应。 其中 R₁ 指烷基、烷氧基或烷氧基羰基，每个烷氧基羰基含有 1-20 个碳原子，R₂ 指光学活性物质
• Glycolate oxidase inhibitors for the treatment of disease
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US11384055B2

  公开（公告）日：2022-07-12

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

  本文描述的是化合物、制造此类化合物的方法、含有此类化合物的药物组合物和药剂，以及使用此类化合物治疗或预防与乙醛酸氧化酶（GO）相关的疾病或紊乱的方法。此类疾病或紊乱包括，例如，与产生过量草酸盐有关的乙醛酸代谢紊乱，包括原发性高草酸尿症。
• GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：BIOMARIN PHARMACEUTICAL INC.

  公开号：US20210171474A1

  公开（公告）日：2021-06-10

  Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
• US4769373A
  申请人：——

  公开号：US4769373A

  公开（公告）日：1988-09-06